(Q50558699)

15 March 2018

title

Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. (English)

1 reference

15 March 2018

1 reference

1 reference

2

1 reference

15 March 2018

author name string

Robert Roomer

series ordinal

1

1 reference

15 March 2018

Harry L A Janssen

series ordinal

3

1 reference

15 March 2018

Robert J de Knegt

series ordinal

4

1 reference

15 March 2018

language of work or name

English

0 references

publication date

1 October 2010

1 reference

15 March 2018

published in

Hepatology

1 reference

15 March 2018

volume

52

1 reference

15 March 2018

issue

4

1 reference

15 March 2018

page(s)

1225-1231

1 reference

15 March 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

cites work

1 reference

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

21 January 2018

1 reference

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.

1 reference

7 January 2021

Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia

1 reference

7 January 2021

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

1 reference

7 January 2021

Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice.

1 reference

7 January 2021

The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin

1 reference

7 January 2021

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

7 January 2021

Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

1 reference

7 January 2021

The evolution of the empirical management of fever and neutropenia in cancer patients

1 reference

7 January 2021

Management of infection in cancer patients. studies of the EORTC International Antimicrobial Therapy Group (IATG).

1 reference

7 January 2021

Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification

1 reference

7 January 2021

Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis.

1 reference

7 January 2021

Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.

1 reference

7 January 2021

The aging of the immune system

1 reference

7 January 2021

Impaired leucocyte functions in diabetic patients

1 reference

7 January 2021

Innate immune response mechanisms in non-insulin dependent diabetes mellitus patients assessed by flow cytoenzymology

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.23842

1 reference

15 March 2018

1 reference

15 March 2018